A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Linnaeus Therapeutics, Inc.
Incyte Corporation
The Netherlands Cancer Institute
Celldex Therapeutics
Eye & ENT Hospital of Fudan University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Massachusetts General Hospital
The Affiliated Hospital of Qingdao University
Peking University Cancer Hospital & Institute
GlaxoSmithKline
University of Utah
AVAX Technologies
Bristol-Myers Squibb
Pfizer
FeRx